RestructuringAug 7, 2026, 04:09 PM
aTyr Pharma Restructures, Cuts 60% Workforce; Q2 Results Announced
AI Summary
aTyr Pharma announced a significant corporate restructuring, including an approximately 60% workforce reduction and program prioritization, to focus resources on its efzofitimod program in interstitial lung disease (ILD). This move is expected to reduce annualized operating expenses by about $13 million and extend the company's cash runway into late 2028. The company also reported its second quarter 2026 financial results, ending the period with $58.9 million in cash and investments and a consolidated net loss of $10.31 million.
Key Highlights
- Workforce reduced by approximately 60% to align resources on efzofitimod program.
- Restructuring and cost savings expected to reduce annualized operating expenses by approximately $13 million.
- Ended Q2 2026 with $58.9 million in cash, cash equivalents, restricted cash, and investments.
- Cash runway extended into late 2028 based on current operations and new expense forecast.
- Q2 2026 R&D expenses were $6.7 million; G&A expenses were $4.1 million.
- Consolidated net loss for Q2 2026 was $10.31 million.
- Awaiting FDA comments by end of August 2026 on Phase 3 efzofitimod protocol for pulmonary sarcoidosis.
- Topline results for Phase 2 EFZO-CONNECT™ study in SSc-ILD expected in Q1 2027.
Price Impact
More from ATYR